spironolactone has been researched along with Benign Neoplasms in 19 studies
Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)
spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment." | 9.10 | Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients? ( Avcu, F; Beyan, C; Cetin, T; Kaptan, K; Nazaroglu, NK; Ural, AU; Yalcin, A, 2002) |
| " This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment." | 5.10 | Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients? ( Avcu, F; Beyan, C; Cetin, T; Kaptan, K; Nazaroglu, NK; Ural, AU; Yalcin, A, 2002) |
| "Thus, in patients with cancer, alopecia can be iatrogenic (chemotherapies, endocrine therapies, targeted therapies, immunotherapies, radiotherapy, surgery) or directly the consequence of the disease itself (malnutrition, scalp metastases, paraneoplastic syndromes)." | 2.72 | [Alopecia and cancers: From basics to clinical practice]. ( Baussard, L; Fiteni, F; Guichard, A; Le Vigouroux, S; Quesada, S, 2021) |
| "Hirsutism is the excessive growth of terminal hair in a typical male pattern in a female." | 2.61 | Hirsutism in Women. ( Bain, J; Matheson, E, 2019) |
| "Hirsutism is defined as excess hair growth in androgen-dependent areas of the body in women." | 2.46 | Hirsutism: Diagnosis and management. ( Brodell, LA; Mercurio, MG, 2010) |
| "Spironolactone use was associated with a significantly lower risk of prostate cancer (hazard ratio 0." | 1.46 | Spironolactone use and risk of incident cancers: a retrospective, matched cohort study. ( MacDonald, TM; Mackenzie, IS; Morant, SV; Thompson, AM; Wei, L, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (42.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Diamandis, P | 1 |
| Wildenhain, J | 1 |
| Clarke, ID | 1 |
| Sacher, AG | 1 |
| Graham, J | 1 |
| Bellows, DS | 1 |
| Ling, EK | 1 |
| Ward, RJ | 1 |
| Jamieson, LG | 1 |
| Tyers, M | 1 |
| Dirks, PB | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Quesada, S | 1 |
| Guichard, A | 1 |
| Le Vigouroux, S | 1 |
| Baussard, L | 1 |
| Fiteni, F | 1 |
| Gold, A | 1 |
| Eini, L | 1 |
| Nissim-Rafinia, M | 1 |
| Viner, R | 1 |
| Ezer, S | 1 |
| Erez, K | 1 |
| Aqaqe, N | 1 |
| Hanania, R | 1 |
| Milyavsky, M | 1 |
| Meshorer, E | 1 |
| Goldberg, M | 1 |
| Matheson, E | 1 |
| Bain, J | 1 |
| Sharma, P | 1 |
| Banerjee, R | 1 |
| Narayan, KP | 1 |
| Mackenzie, IS | 1 |
| Morant, SV | 1 |
| Wei, L | 1 |
| Thompson, AM | 1 |
| MacDonald, TM | 1 |
| Brodell, LA | 1 |
| Mercurio, MG | 1 |
| Demirer, T | 1 |
| Ayli, M | 1 |
| Dagli, M | 1 |
| Fen, T | 1 |
| Haznedar, R | 1 |
| Ustael, N | 1 |
| Ustun, T | 1 |
| Oymak, A | 1 |
| Ozdel, O | 1 |
| Muftuoglu, O | 1 |
| GOLINELLI, G | 1 |
| MELLI, A | 1 |
| ABBES, M | 1 |
| CAMBON, P | 1 |
| PAILLAUD, F | 1 |
| GEOKAS, MC | 1 |
| CHUN, JY | 1 |
| DINAN, JJ | 1 |
| BECK, IT | 1 |
| Christian, N | 1 |
| Bol, A | 1 |
| De Bast, M | 1 |
| Labar, D | 1 |
| Lee, J | 1 |
| Mahy, P | 1 |
| Grégoire, V | 1 |
| Kley, HK | 1 |
| Ross, HD | 1 |
| Ural, AU | 1 |
| Avcu, F | 1 |
| Cetin, T | 1 |
| Beyan, C | 1 |
| Kaptan, K | 1 |
| Nazaroglu, NK | 1 |
| Yalcin, A | 1 |
| Kvedar, JC | 1 |
| Gibson, M | 1 |
| Krusinski, PA | 1 |
| Greenblatt, DJ | 1 |
| Koch-Weser, J | 1 |
| Walser, M | 1 |
6 reviews available for spironolactone and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
[Alopecia and cancers: From basics to clinical practice].
Topics: Alopecia; Antihypertensive Agents; Antineoplastic Agents; Bimatoprost; Hair; Hair Follicle; Humans; | 2021 |
Hirsutism in Women.
Topics: Adrenal Hyperplasia, Congenital; Androgen Antagonists; Antineoplastic Agents, Hormonal; Contraceptiv | 2019 |
Hirsutism: Diagnosis and management.
Topics: 5-alpha Reductase Inhibitors; Adrenal Hyperplasia, Congenital; Causality; Contraceptives, Oral; Diag | 2010 |
Hirsutism: evaluation and treatment.
Topics: Contraceptives, Oral; Dehydroepiandrosterone; Dexamethasone; Dihydrotestosterone; Female; Hair Remov | 1985 |
Treatment of hypercalcemias.
Topics: Administration, Oral; Calcitonin; Calcium, Dietary; Citrates; Diuretics; Edetic Acid; Ethacrynic Aci | 1970 |
2 trials available for spironolactone and Benign Neoplasms
| Article | Year |
|---|---|
The effect of post-transplant spironolactone on daily potassium requirements in patients undergoing autologous stem cell transplantation.
Topics: Adolescent; Adult; Diuretics; Female; Humans; Hypokalemia; Male; Middle Aged; Neoplasms; Peripheral | 2002 |
Spironolactone: is it a novel drug for the prevention of amphotericin B-related hypokalemia in cancer patients?
Topics: Amphotericin B; Antifungal Agents; Humans; Hypokalemia; Kidney Function Tests; Mineralocorticoid Rec | 2002 |
11 other studies available for spironolactone and Benign Neoplasms
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutic | 2007 |
Spironolactone inhibits the growth of cancer stem cells by impairing DNA damage response.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Repair; Dru | 2019 |
Mineralocorticoid receptor mediated liposomal delivery system for targeted induction of apoptosis in cancer cells.
Topics: Animals; Apoptosis; CHO Cells; Cricetinae; Cricetulus; Gene Transfer Techniques; HEK293 Cells; Human | 2016 |
Spironolactone use and risk of incident cancers: a retrospective, matched cohort study.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Female; Humans; Incidence; Male; Middle Aged; | 2017 |
[POTENTIATION OF MERCURIAL DIURETICS WITH PROGESTERONE].
Topics: Chemistry, Pharmaceutical; Diuretics; Edema; Heart Failure; Liver Cirrhosis; Mineralocorticoid Recep | 1964 |
[APPLICATION OF ANTI-ALDOSTERONE DIURETICS TO THE TREATMENT OF LOCALIZED EDEMA OF THE EXTREMITIES IN CANCER PATIENTS].
Topics: Aldosterone; Breast Neoplasms; Diuretics; Edema; Extremities; Female; Humans; Mastectomy; Mineraloco | 1965 |
ISLET-CELL CARCINOMA (ZOLLINGER-ELLISON SYNDROME) WITH FULMINATING ADRENOCORTICAL HYPERFUNCTION AND HYPOKALEMIA.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adenoma, Islet Cell; Adrenalectomy; Adrenocortical Hyper | 1965 |
Determination of tumour hypoxia with the PET tracer [18F]EF3: improvement of the tumour-to-background ratio in a mouse tumour model.
Topics: Animals; Area Under Curve; Hypoxia; Liver; Male; Mice; Mice, Inbred C3H; Neoplasms; Nitroimidazoles; | 2007 |
[Diagnostic procedures in gynecomastia].
Topics: Adolescent; Adult; Diagnosis, Differential; Digitalis; Estradiol Congeners; Gynecomastia; Humans; Hy | 1984 |
Tumorigenic aspect of spironolactone.
Topics: Hirsutism; Humans; Neoplasms; Spironolactone | 1981 |
Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program.
Topics: Adult; Aged; Blood Urea Nitrogen; Coma; Dehydration; Diarrhea; Female; Gynecomastia; Headache; Heart | 1973 |